Can lithium be used in the setting of clozapine commencement in patients with COVID-19 associated neutropenia: A case report
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.COVID-19 infection can raise neutropenia risk in patients taking clozapine. Lithium may be a beneficial add-on treatment for these individuals experiencing neutropenia during COVID-19.
Area Of Science
- Pharmacology
- Infectious Diseases
- Hematology
Background
- Clozapine is an essential atypical antipsychotic medication.
- Neutropenia is a serious adverse effect of clozapine therapy.
- COVID-19 is a global pandemic with potential hematological impacts.
Observation
- COVID-19 infection may be associated with an increased risk of neutropenia in patients undergoing clozapine treatment.
- This observation highlights a potential drug-drug-disease interaction.
Findings
- The study suggests a correlation between COVID-19 infection and heightened neutropenia risk among clozapine users.
- Adjunct lithium therapy is proposed as a potential management strategy.
Implications
- Clinicians should monitor clozapine-treated patients closely for neutropenia during COVID-19 infection.
- Lithium may serve as an important therapeutic option to mitigate clozapine-associated neutropenia in the context of COVID-19.
- Further research is warranted to confirm the efficacy and safety of lithium in this specific clinical scenario.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.